GEN Exclusives

More »

GEN News Highlights

More »
Apr 22, 2013

Horizon, AstraZeneca Seek Kinase-Targeting Cancer Drugs

  • Horizon Discovery and AstraZeneca are teaming up to explore Horizon’s first-in-class kinase target program, HD-001, as a means of developing novel therapies for multiple cancer types. Horizon will receive undisclosed up-front and preclinical milestone payments, and is eligible for clinical and approval milestones totaling up to $75 million, as well as tiered royalties.

    The firms say that the HD-001 program, currently in the early stages, has the potential to be developed into a treatment based on modulation of a novel kinase. This target has been shown to be mutated in a range of cancer types including colon and lung. The target has also been shown to play a key role in K-Ras mutant tumors. K-Ras is mutated in up to 40% of all cancer types causing resistance to many of the available targeted therapeutics and as a result is associated with poor patient outcomes.

    “The program has benefitted greatly from the use of Horizon’s drug discovery toolbox to first exquisitely validate the target and then provide a range of ‘on-target’ cellular assays to support rational drug discovery,” Darrin M. Disley, Ph.D., CEO at Horizon Discovery, said. “As a result, the lead discovery effort has been rapid, resulting in a diverse portfolio of potent and selective inhibitors of the target.”

    In a separate deal said to be worth over $200 million, AZ will also be working with BIND Therapeutics to develop and commercialize a targeted and programmable cancer nanomedicine. Find out more about that deal here.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?